Evidence map›Paper›PMID 39833068›Full record

Observational studyMedicine2025

Evaluation of the impact of refined nursing care on schizophrenia patients.

Yuanling Zhang, Wenbin Liang, Jiao Gui

Abstract readObservational Study
In one paragraph

Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuanling ZhangDepartment of PICU2, Wudong Hospital of Wuhan, Wuhan, Hubei, China.ORCID 0009-0005-0638-0213
Wenbin Liang
Jiao Gui

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study evaluates the impact of refined nursing interventions on patients with schizophrenia, focusing on disease severity, cognitive function, medication adherence, quality of life, and medication-related complications. The aim is to provide evidence for enhancing future clinical treatments. From January 2022 to January 2024, 201 schizophrenia patients were enrolled based on specific inclusion and exclusion criteria. Patients were allocated into 2 groups using propensity score matching: an experimental group that received refined nursing care and a control group that received routine care. Outcome measures included Positive and Negative Syndrome Scale scores, cognitive assessments (Mini-Mental State Examination and Nurses' Observation Scale for Inpatient Evaluation), medication adherence, quality of life, relapse rates, and medication-related side effects. After propensity score matching, baseline characteristics of the experimental and control groups were comparable. Following nursing interventions, the experimental group demonstrated significant improvements in Positive and Negative Syndrome Scale scores, cognitive assessments (Mini-Mental State Examination and Nurses' Observation Scale for Inpatient Evaluation), medication adherence, and quality of life compared to the control group. The experimental group also showed lower relapse rates and fewer medication side effects, confirming the enhanced effectiveness of refined nursing interventions. Refined nursing care significantly improved disease outcomes, cognitive function, medication adherence, and quality of life in schizophrenia patients, while reducing relapse rates and medication-related complications, highlighting its clinical value in psychiatric care.

Indexed as

Nursing CareSchizophreniaAdultAntipsychotic AgentsCognitionFemaleHumansMaleMedication AdherenceMiddle AgedPropensity ScoreQuality of LifeAntipsychotic Agents

Identifiers

PMID39833068
PMCPMC11749742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.